CONCLUSIONS
Finally, adopting MICi, a comprehensive concept, a new PK/PD analysis approach for β-lactam/β-lactamase inhibitor combination therapy was developed. In comparison to existing PK/PD parameters (f T>CT), the PK/PD parameters (f T>MICi) and their target values in this newly designed PK/PD analysis approach were more practical, generic, and accurate. PK/PD analysis employingf T>MICi might theoretically be used in β-lactam/β-lactamase inhibitor combination therapy and antimicrobial/antimicrobial combination therapy. Furthermore, this is the first report of aztreonam/nacubactam being effective against carbapenemase-producing K. pneumoniae , particularly NDM-producingK. pneumoniae . By improving the treatment of drug-resistant bacterial infections, this study’s findings should help improve human health and welfare.